$2.7bil in total revenue at $750 per unit (Qbrexzas price).
or $1.94bil profit at $540 per unit.
Being 3% of the 10m suffers aka 8% of the patients that are currently seeking treatment (3.7m) from a dermatologist. both seem very achievable.
they say when you start a new biotech product you should be assuming at least 10% market share.
Being a first line treatment you'd expect dermatologists to be easily be recommending this to more than 1 in 10 patients that come to see them bout this issue.
Ann: Botanix Commercial Day Webinar Presentation, page-155
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.005(1.18%) |
Mkt cap ! $761.8M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.5¢ | 41.5¢ | $2.435M | 5.697M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 819538 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 29052 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |